Experience

Alzheon, Inc. | Preserving Future Memories

• United States
• Biotechnology Research
• 1 - 100 Employee

• VP of Program and Portfolio Management

  • Jun 2015 - Present

  Framingham, MA Alzheon, Inc. is committed to developing innovative medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders. Our lead clinical candidate, ALZ-801, is a first-in-class, oral inhibitor of amyloid aggregation and neurotoxicity - hallmarks of Alzheimer’s disease. ALZ-801 is an optimized, novel prodrug that builds on the established safety and efficacy profile of the active compound in clinical trials of more than 2,000 patients. Our mission is to… Show more Alzheon, Inc. is committed to developing innovative medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders. Our lead clinical candidate, ALZ-801, is a first-in-class, oral inhibitor of amyloid aggregation and neurotoxicity - hallmarks of Alzheimer’s disease. ALZ-801 is an optimized, novel prodrug that builds on the established safety and efficacy profile of the active compound in clinical trials of more than 2,000 patients. Our mission is to apply our discovery platform and development experience to unlock new classes of therapeutics that make a difference in patients’ lives by directly addressing the underlying pathology of devastating neurodegenerative disorders. www.alzheon.com Show less



Pfizer

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Strategy & Portfolio Solutions Lead

  • Jun 2014 - Nov 2014

  Groton, CT Leading projects focused on the application of big data and predictive analytics to drug development and external collaborations for drug repositioning.

• Vice President and Head of PharmaTherapeutics Precision Medicine

  • Jan 2011 - May 2014

  Groton Connecticut Group mission is to optimize the development of new medicines and enable Precision Medicine through innovative applications of clinical and molecular science and technology. Primary focus of the group is to identify and provide human biology validation of targets, support the selection of populations and indications and develop biomarkers to support the delivery of successful Proof of Concept through the application of imaging, human genetics and translational genomics.

• Head of Molecular Medicine

  • Jan 2008 - Jan 2011

  Global group with colleagues at five different Pfizer sites consists of laboratories in proteomics and pharmacogenomics as well groups in computational sciences, physiological measurements, diagnostics and imaging supporting the portfolio of Pfizer products from Research through post-marketing.

• Head of Health Technologies, Translational and Molecular Medicine

  • May 2007 - Jan 2008

  Greater New York City Area Led a group in New York towards the development of clinical and molecular technologies in support of the Global Medical and Commercial organizations.

• TA Group Lead Molecular Profiling

  • Aug 2005 - May 2007

  New London, CT Led the development of integrated strategies for the application of multiple technologies and biomarkers across all disease areas in support of development and marketed programs.



Pfizer

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Head of Clinical Pharmacogenetics/Pharmacogenomics

  • Apr 1998 - Apr 2005

  Sandwich UK and New London, Connecticut Established Clinical Pharmacogenetics as a discipline at Pfizer. Recruited and established the group in the UK and subsequently in the US. Oversaw biobanking activities including establishing one of the first large scale automation biobanks at -80C.

• Clinical Project Manager/Senior Clinical Project Manager

  • Aug 1993 - Apr 1998

  Sandwich, UK Responsible for designing and managing phase III clinical studies (ziprasidone and sertraline) conduct in Europe and globally (South Africa, Australia). Also responsible for leading efforts to develop a phase III planning for the European arm of a global program for a novel anxiety drug - eventually the compound did not make it to Phase III.



Clinical Training

• Various hospital training programs in medicine and psychiatry

  • Jul 1984 - Aug 1993

  Cork, Ireland; London, Aylesbury, and Oxford UK Following graduation in Ireland in 1984 I completed my internship at the South Infirmary, Cork and then completed one year Senior House Officer (SHO) training in General Medicine at Waterford Regional Hospital, I did a six month SHO position in Geriatric Medicine at Dulwich Hospital North in London before joining the Aylesbury Vale Health Authority rotational training scheme in Psychiatry during which time I completed my Member of the Royal College of Psychiatrist training. I did… Show more Following graduation in Ireland in 1984 I completed my internship at the South Infirmary, Cork and then completed one year Senior House Officer (SHO) training in General Medicine at Waterford Regional Hospital, I did a six month SHO position in Geriatric Medicine at Dulwich Hospital North in London before joining the Aylesbury Vale Health Authority rotational training scheme in Psychiatry during which time I completed my Member of the Royal College of Psychiatrist training. I did Pscyhopharmacology research at the Littlemore Hospital - MRC Unit working with Phil Cowen - and joined the Oxford Senior Registrar training scheme before moving to Pfizer in August 1993 Show less